AgomAb Therapeutics (NASDAQ:AGMB) Sees Strong Trading Volume – Here’s Why

AgomAb Therapeutics NV (NASDAQ:AGMB) saw strong trading volume on Thursday . 179,998 shares were traded during trading, an increase of 37% from the previous session’s volume of 131,503 shares.The stock last traded at $14.1140 and had previously closed at $13.66.

Wall Street Analyst Weigh In

AGMB has been the subject of several analyst reports. HC Wainwright started coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company. Piper Sandler started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They set an “overweight” rating on the stock. B. Riley Financial started coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. Finally, Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.50.

AgomAb Therapeutics Stock Performance

The firm has a 50-day simple moving average of $13.28.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. As a group, equities analysts forecast that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.